|
1.
|
Steinman RM: The dendritic cell system and
its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Gong J, Chen D, Kashiwaba M and Kufe D:
Induction of antitumor activity by immunization with fusions of
dendritic and carcinoma cells. Nat Med. 3:558–561. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gong J, Koido S and Calderwood SK: Cell
fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev
Vaccines. 7:1055–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Koido S, Homma S, Okamoto M, et al:
Fusions between dendritic cells and whole tumor cells as anticancer
vaccines. Oncoimmunology. 2:e244372013. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yanagimoto H, Takai S, Satoi S, et al:
Impaired function of circulating dendritic cells in patients with
pancreatic cancer. Clin Immunol. 114:52–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Colonna M, Trinchieri G and Liu YJ:
Plasmacytoid dendritic cells in immunity. Nat Immunol. 5:1219–1226.
2004. View
Article : Google Scholar
|
|
7.
|
Liu YJ: IPC: professional type 1
interferon-producing cells and plasmacytoid dendritic cell
precursors. Annu Rev Immunol. 23:275–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kim R, Emi M, Tanabe K and Arihiro K:
Potential functional role of plasmacytoid dendritic cells in cancer
immunity. Immunology. 121:149–157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Segura E, Kapp E, Gupta N, et al:
Differential expression of pathogen-recognition molecules between
dendritic cell subsets revealed by plasma membrane proteomic
analysis. Mol Immunol. 47:1765–1773. 2010. View Article : Google Scholar
|
|
10.
|
Mouries J, Moron G, Schlecht G, Escriou N,
Dadaglio G and Leclerc C: Plasmacytoid dendritic cells efficiently
cross-prime naive T cells in vivo after TLR activation. Blood.
112:3713–3722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Narita M, Watanabe N, Yamahira A, et al: A
leukemic plasmacytoid dendritic cell line, PMDC05, with the ability
to secrete IFN-alpha by stimulation via Toll-like receptors and
present antigens to naive T cells. Leuk Res. 33:1224–1232. 2009.
View Article : Google Scholar
|
|
12.
|
Watanabe N, Narita M, Yamahira A, et al:
Transformation of dendritic cells from plasmacytoid to myeloid in a
leukemic plasmacytoid dendritic cell line (PMDC05). Leuk Res.
34:1517–1524. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yamahira A, Narita M, Nakamura T, et al:
Generation of antigen-specific cytotoxic T lymphocytes using a
leukemic plasmacytoid dendritic cell line as antigen presenting
cells. Leuk Res. 35:793–799. 2011. View Article : Google Scholar
|
|
14.
|
Yamahira A, Narita M, Ishii K, et al:
Enhancement of antigen presenting ability in the leukemic
plasmacytoid dendritic cell line (PMDC05) by lentiviral
vector-mediated transduction of CD80 gene. Leuk Res. 36:1541–1546.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Koido S, Hara E, Homma S, et al:
Dendritic/pancreatic carcinoma fusions for clinical use:
comparative functional analysis of healthy-versus patient-derived
fusions. Clin Immunol. 135:384–400. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Koido S and Gong J: Characterization of
structure and direct antigen presentation by dendritic/tumor-fused
cells as cancer vaccines. Anticancer Res. 33:347–354.
2013.PubMed/NCBI
|
|
17.
|
Liu L, Chahroudi A, Silvestri G, et al:
Visualization and quantification of T cell-mediated cytotoxicity
using cell-permeable fluorogenic caspase substrates. Nat Med.
8:185–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Lapteva N, Seethammagari MR, Hanks BA, et
al: Enhanced activ ation of human dendritic cells by inducible CD40
and Toll-like receptor-4 ligation. Cancer Res. 67:10528–10537.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Luger R, Valookaran S, Knapp N,
Vizzardelli C, Dohnal AM and Felzmann T: Toll-like receptor 4
engagement drives differentiation of human and murine dendritic
cells from a pro- into an anti-inflammatory mode. PLoS One.
8:e548792013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Koido S, Homma S, Okamoto M, et al:
Combined TLR2/4-activated dendritic/tumor cell fusions induce
augmented cytotoxic T lymphocytes. PLoS One. 8:e592802013.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kimura T and Finn OJ: MUC1 immunotherapy
is here to stay. Expert Opin Biol Ther. 13:35–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Brugger W, Buhring HJ, Grunebach F, et al:
Expression of MUC-1 epitopes on normal bone marrow: implications
for the detection of micrometastatic tumor cells. J Clin Oncol.
17:1535–1544. 1999.PubMed/NCBI
|
|
23.
|
Wykes M, MacDonald KP, Tran M, et al: MUC1
epithelial mucin (CD227) is expressed by activated dendritic cells.
J Leukoc Biol. 72:692–701. 2002.PubMed/NCBI
|
|
24.
|
Koido S, Hara E, Homma S, et al:
Streptococcal preparation OK-432 promotes fusion efficiency and
enhances induction of antigen-specific CTL by fusions of dendritic
cells and colorectal cancer cells. J Immunol. 178:613–622. 2007.
View Article : Google Scholar
|
|
25.
|
Koido S, Hara E, Homma S, et al: Dendritic
cells fused with allogeneic colorectal cancer cell line present
multiple colorectal cancer-specific antigens and induce antitumor
immunity against autologous tumor cells. Clin Cancer Res.
11:7891–7900. 2005. View Article : Google Scholar
|
|
26.
|
Koido S, Hara E, Homma S, Ohkusa T, Gong J
and Tajiri H: Cancer immunotherapy by fusions of dendritic cells
and tumor cells. Immunotherapy. 1:49–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Haenssle HA, Krause SW, Emmert S, et al:
Hybrid cell vaccination in metastatic melanoma: clinical and
immunologic results of a phase I/II study. J Immunother.
27:147–155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Trefzer U, Herberth G, Wohlan K, et al:
Tumour-dendritic hybrid cell vaccination for the treatment of
patients with malignant melanoma: immunological effects and
clinical results. Vaccine. 23:2367–2373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lundqvist A, Palmborg A, Bidla G, Whelan
M, Pandha H and Pisa P: Allogeneic tumor-dendritic cell fusion
vaccines for generation of broad prostate cancer T-cell responses.
Med Oncol. 21:155–165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Matsumoto S, Saito H, Tsujitani S and
Ikeguchi M: Allogeneic gastric cancer cell-dendritic cell hybrids
induce tumor antigen (carcinoembryonic antigen) specific CD8(+) T
cells. Cancer Immunol Immunother. 55:131–139. 2006.PubMed/NCBI
|
|
31.
|
Marten A, Renoth S, Heinicke T, et al:
Allogeneic dendritic cells fused with tumor cells: preclinical
results and outcome of a clinical phase I/II trial in patients with
metastatic renal cell carcinoma. Hum Gene Ther. 14:483–494. 2003.
View Article : Google Scholar
|
|
32.
|
Siders WM, Garron C, Shields J and Kaplan
JM: Induction of antitumor immunity by semi-allogeneic and fully
allogeneic electrofusion products of tumor cells and dendritic
cells. Clin Transl Sci. 2:75–79. 2009. View Article : Google Scholar : PubMed/NCBI
|
